Thematic area:
Novel Sensors
Product:
A next generation neuromuscular blockade monitoring device that measures pre-threshold motor endplate potentials, providing accurate real-time visibility of paralysis depth during surgery and ICU care. It outperforms the decades-old Train of Four (ToF) technique.
Market:
Serves a >€400M annual opportunity in the US and UK alone, across surgery, anaesthesia, and intensive care. Supported by engagement with Vitalograph, offering strong clinical industry integration and potential for licensing.
Fit:
Current monitoring methods are crude and subjective. NMB Sentinel provides objective, high resolution monitoring, reduces drug waste, and improves patient safety – a strong commercial fit validated by clinicians and regulatory planning.
